Shineco

43 articles about Shineco

• Shineco Regains Compliance with Nasdaq Minimum Bid Price Requirement

  3/12/2024

  Shineco, Inc. announced that on March 11, 2024, the Company received formal notice from the Listing Qualifications Department of The Nasdaq Stock Market indicating that the Company has evidenced compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule5550.

• Shineco Announces 1-for-10 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement

  2/14/2024

  Shineco, Inc. announced that the Company’s Board of Directors has approved a reverse stock split of its issued and outstanding shares of common stock, par value $0.001 per share, at a ratio of 1-for-10.

• Shineco to Increase R&D to Explore New High-Tech Medical Product Applications

  10/4/2023

  Shineco, Inc. announced that it plans to increase its research and development of new high-tech applications of silk protein in the health and medical field in conjunction with its existing silkworm business segment.

• Shineco Enters into Cooperation Agreement with Kangling Medical to Develop New Medical Products Company

  6/28/2023

  Shineco, Inc. announced that on June 15, 2023, its wholly owned subsidiary, Shineco Life Science Research Co., Ltd., signed a joint venture cooperation agreement with Yangzhou Kangling Medical Co., Ltd., to establish a joint venture company, Shangkang Life Science and Technology Co., Ltd.

• Shineco Subsidiary Registered as a Member of Pharmaceutical Chamber of Commerce

  6/8/2023

  Shineco, Inc., a provider of technologically advanced healthcare products and services, announced that in May 2023, its wholly owned subsidiary.

• Shineco Entered Into Framework Agreement Relating to Acquisition of Antiviral Fabric Producer Chongqing Wintus Group

  1/17/2023

  Shineco, Inc. announced that on January 13, 2023, the Company entered into a non-binding framework agreement with certain shareholders of Dream Partner Limited to acquire 80% equity interests of Dream Ltd., which indirectly owns 100% equity interests of Chongqing Wintus Group, which is a private company based in China that produces specialized antiviral silk fabric materials that can be widely used in the medical, hygiene, pharmaceutical and personal health fields.

• Shineco, Inc Subsidiary, Granted USPTO Patent and FDA Marketing Approval for Its In-situ Fecal Specimen Sampling Device

  12/7/2022

  Shineco, Inc. announced that its controlling affiliate, Changzhou Biowin Pharmaceutical Co., Ltd., has been granted a patent by the United States Patent and Trademark Office protecting its in-situ fecal specimen sampling device for the use of stool test sample collection, and the marketing approval of the product by the Food and Drug Administration.

• Shineco, Inc. Attends MEDICA 2022 Düsseldorf Germany

  11/29/2022

  Shineco, Inc. announced that the Company’s controlling affiliate Changzhou Biowin Pharmaceutical Co., Ltd., a Chinese biotechnology company focusing on in-vitro diagnostic product research and development and high-tech biomedical products manufacturing, attended MEDICA 2022 in Düsseldorf, Germany from November 14 to 17, 2022.

• Shineco, Inc. to Acquire Controlling Equity Interest in Changzhou Biowin Pharmaceutical Co., Ltd to Step into Point-of-Care Testing Industry

  10/25/2022

  Shineco, Inc. announced that on October 21, 2022, the Company, through its wholly-owned subsidiary, Shineco Life Science Research Co., Ltd., entered into a Stock Purchase Agreement to acquire 51% of the issued equity interest of Changzhou Biowin Pharmaceutical Co., Ltd., a Chinese biotechnology company focusing on in-vitro diagnostic product research and development and high-tech biomedical products manufacturing.

• Shineco, Inc. to Build Its First Tumor Classification Diagnosis and Treatment Center in Weifang City, Shandong Province

  3/11/2022

  Shineco, Inc. announced that on March 4, 2022, the Company has signed a strategic cooperation framework agreement on Shineco’s Weifang Life Science Industrial Park Project with the Development Service Center of Weifang Binhai Science and Technology Innovation Park in Shandong Province to build one of China's first city-level tumor classification diagnosis and treatment centers and an online telemedicine service platform, which would constitute Shineco’s tumor diagnosis and treatment platform.

• Shineco, Inc. to Create an Industry-University-Research-Medical Collaborative Platform for Psychological Rehabilitation of Tumor Patients

  2/24/2022

  Shineco, Inc. announced that the Company entered into a strategic cooperation agreement with Beijing Xihuan Psychological Consulting Co., Ltd., a Beijing-based comprehensive psychological consulting company, on February 21, 2022 to jointly build an industry-university-research-medical collaborative platform for psychological rehabilitation of tumor patients.

• Shineco, Inc. Enters Into Cooperation Agreement to Jointly Manufacture PET and Explore High-end Medical Imaging Devices Field

  2/3/2022

  Shineco, Inc. announced that on January 30, 2022, the Company entered into certain cooperation agreement with Weifang Jianyi Medical Devices Co., Ltd. to jointly manufacture and sell nuclear medicine imaging devices, including PET, PET-CT, and PET-MRI, for comprehensively improving the quality of imaging examination and diagnosis and treatment of specialized hospitals for tumor.

• Shineco, Inc. Appoints Professor Qiyin Sun as Chief Medical Consultant

  2/1/2022

  Shineco, Inc., a producer and distributor of Chinese herbal medicines, organic agricultural and other biotech products, announced that the Company has appointed Professor Qiyin Sun as the Chief Medical Consultant.

• Shineco, Inc. Announces Entering Into a Securities Purchase Agreement with GHS Investments, LLC with Gross Proceeds of $2.0 Million USD

  12/6/2021

  Shineco, Inc. announced that it has entered into a securities purchase agreement for the sale of Gross Proceeds US$2.0 million of its registered common stock at a price of $6.8546 per share with GHS Investments, LLC, a leading private investment and management group providing financial solutions for high potential small cap enterprises.

• Shineco, Inc. Intends to Acquire a Controlling Interest of Xiang Peng You Kang (Beijing) Technology Co., Ltd., a Healthcare Services Company

  12/3/2021

  Shineco, Inc. announced that on November 18, 2021, it entered into non-binding framework agreements (the "Framework Agreements") with certain shareholders of Xiang Peng You Kang (Beijing) Technology Co., Ltd.

• Shineco, Inc. Announces Nasdaq Ticker Symbol Change from "TYHT" to "SISI"

  10/15/2021

  Shineco, Inc. announced that its ticker symbol on the Nasdaq Stock Market (NASDAQ) will change to "SISI" at the open of market trading on Monday, October 18, 2021.

• 

  Global Roundup: BICO Group Acquires QInstruments and More

  10/7/2021

  Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

• Shineco, Inc. Announces It’s Unaware of Reason for Stock Volatility

  6/1/2021

  Shineco, Inc., a producer and distributor of Chinese herbal medicines, organic agricultural and hemp products, announced in response to unusual market activity, and after speaking with its officers, directors, major shareholders and other relevant persons, that it is unaware of the reason behind recent stock price volatility.

• Shineco, Inc. Announces Appointment of New CEO

  5/7/2021

  Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: TYHT), a producer and distributor of Chinese herbal medicines, organic agricultural and hemp products, today announced that Mr. Guocong Zhou had step down as CEO of the Company, effective May 5, 2021.

• Shineco, Inc. Proposes to Acquire 51% Equity Interests in Mayah Biological Holdings Limited

  5/4/2021

  Shineco, Inc. announced the Company and Mayah Biological Holdings Limited, a British Virgin Islands Company headquartered in Taiwan Biomedical Park, had signed a Proposal for Purchase of Equity Interest of Mayah Biological Holding Limited, with respect to the potential purchase of at least 51% equity interests in Mayah Biological by the Company.